Pharmaasia Limited announced a substantial turnaround in its financial performance for the fiscal year ended March 31, 2026. The company reported a net profit of ₹1757.28 Lakhs, a significant improvement from a net loss of ₹158.94 Lakhs in the previous fiscal year. Revenue from operations also saw a substantial increase, growing to ₹4720.75 Lakhs.
Pharmaasia Ltd. Reports Strong Financial Turnaround in FY26
Pharmaasia Limited has achieved a significant financial turnaround for the fiscal year ended March 31, 2026. The company reported a notable net profit of ₹1757.28 Lakhs, a substantial improvement compared to the net loss of ₹158.94 Lakhs recorded in the previous fiscal year. This positive shift highlights a robust recovery and strengthened financial position for the company.
Revenue Growth and Profitability
The company’s revenue from operations for FY 2025-26 stood at ₹4720.75 Lakhs, marking a considerable increase from the ₹2436.88 Lakhs reported in the prior year. This growth in revenue, coupled with effective cost management, has directly contributed to the company’s return to profitability. The earnings per share (EPS) also saw a dramatic improvement, increasing to ₹25.74 from a negative ₹2.33 in the previous year.
Operational Highlights
The Directors’ Report indicates that the company’s primary business remains the manufacturing and marketing of oral contraceptives and iron tablets. There have been no changes in the nature of the business during the year. The company also reported a change in its registered office during the financial year, effective from February 6, 2026.
Related Party Transactions and Remuneration
The company is seeking shareholder approval for related party transactions not exceeding ₹100 crores for the financial year 2026-27. Additionally, the Board has proposed a revision in the remuneration of Mr. Naga Bhaskara Rao, Whole-Time Director, increasing his CTC to ₹38,50,000/- per annum, subject to member approval.
Source: BSE
